Ethambutol, isoniazid, pyrazinamide, rifampicin (Myrin-p Forte)
Ethambutol, isoniazid, pyrazinamide, rifampicin
Pfizer Laboratories (Pty) Ltd
Every registration of this product has been cancelled.
Registration
- Applicant
- Pfizer Laboratories (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Myrin-p forte EACH TABLET CONTAINS ETHAMBUTOL 275,0 mg ISONIAZID 75,0 mg PYRAZINAMIDE 400,0 mg RIFAMPICIN 150,0 mg | Not listed | 37066737/20.2.3/0667 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Ethambutol
Consolidated Schedules 06 July 2026, line 6284
S4: Isoniazid
Consolidated Schedules 06 July 2026, line 6819
S4: Pyrazinamide
Consolidated Schedules 06 July 2026, line 7685
S4: Rifampicin
Consolidated Schedules 06 July 2026, line 7802
S3: Pyrazinamide
- when intended for oral use.
Consolidated Schedules 06 July 2026, line 4189
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.